Guselkumab is a monoclonal antibody used to treat moderate to severe plaque psoriasis. Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23.
- Mechanism
- Curator reviewed · 3 references
Guselkumab targets the p19 alpha subunit of IL-23. While IL-23 promotes the normal inflammatory and immune responses, the p19 and p40 subunits of IL-23 are found to be over-expressed in the condition of psoriasis and other autoimmune inflammatory skin diseases. Guselkumab selectively binds to the p19 subunit of IL-23 in dendritic cells and keratinocytes and blocks its interaction with IL-23 receptor, which further prevents the release of other pro-inflammatory cytokines and chemokines via stimulation of immune cells such as Th17 cells. Thus, guselkumab blocks the abnormally-heightened signalling of inflammatory cascades that promote epidermal abnormalities including keratinocyte hyperproliferation and psoriatic plaque formation.
- Primary indication
- Guselkumab is indicated for: the treatment of adults and pediatric patients 6 years of age and older who also weigh at least 40 kg with moderate-to-severe plaque psoriasis and who are candidates for systemic therapy...Curator reviewed · 7 structured indications
- Formula / weight
- C6402H9864N1676O1994S42 · 143.6 Da (units in kg/mol)
- First approval
- Canada, 2017 · United States, 2017 · European Union, 2020
- Code names
- CNTO1959
- Brand names
Resolves to
What you can answer from here — as of September 29, 2025
Which drugs share a target with Guselkumab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account